Contact lens care solution for inhibiting corneal hypoxia injury and corneal neovascularization and preparation method thereof
By adding ingredients such as acetonin A to contact lens care solution, the corneal hypoxia and neovascularization problems caused by contact lens wear are solved, safe and effective prevention of local applications are achieved, side effects of systemic use are avoided, and significant Health care effects.
Patent Information
- Application Number
- CN202411093320.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-09
AI Technical Summary
Corneal hypoxia and neovascular problems caused by wearing contact lenses, there is no effective contact lens care solution that can effectively inhibit this problem, and the use of ashlotin A systemic system has cardiovascular and cerebrovascular side effects.
Develop a contact lens care solution containing alcoholic solanocin A, disodium edeate, solvent-promoting agent, thickening agent, antibacterial agent and pH regulator. The local application of alcoholic solanocin A is to inhibit corneal hypoxia damage and regeneration Vascular formation avoids the side effects of systemic administration.
This care solution has good solubility and biocompatibility, directly acts on the cornea, significantly improves corneal hypoxia and neovascularization, provides preventive health care functions, is easy to use and is not irritating.
Smart Images

Figure HDA0004987178380000011 
Figure HDA0004987178380000012
Abstract
Description
Technical Field
[0001] The invention relates to a contact lens care solution, and in particular to a contact lens care solution capable of inhibiting corneal hypoxia damage and corneal neovascularization, and a preparation method thereof. Background Art
[0002] Wearing contact lenses, especially long-term wear, can easily cause corneal hypoxia and lead to the appearance of corneal neovascularization. The cornea is a transparent tissue in the front of the eye, which has no blood vessels under normal circumstances. It mainly obtains oxygen through the exchange of air and tears. Contact lenses, especially lenses with low oxygen permeability (such as cosmetic lenses), will cover the surface of the cornea, reducing the contact between the cornea and the air, thereby affecting the oxygen permeability of the cornea and causing corneal hypoxia and damage. When the cornea is in a state of hypoxia for a long time, vascular endothelial growth factor (VEGF) will stimulate the vascular network at the edge of the cornea to grow toward the center of the cornea to form new blood vessels. Long-term wear of contact lenses may also cause chronic inflammation or micro-damage to the cornea, which will further promote the formation of new blood vessels. Corneal neovascularization will not only affect the transparency of the cornea and lead to decreased vision, but may also cause other serious eye problems, such as corneal ulcers, corneal epithelial detachment, etc., and may even lead to blindness. Therefore, corneal tissue hypoxia and corneal neovascularization are the biggest hidden dangers for people wearing contact lenses.
[0003] Our team's previous research confirmed that Withaferin A, a compound extracted from South African somniferum, has dual effects of anti-hypoxic damage and anti-VEGF, and may become a potential ocular drug (patent number: 201910398536.6, disclosing a "Application of Withaferin A in the Preparation of Drugs for the Treatment of Fundus Ischemic Diseases"). However, this invention is to use a subperitoneal implantation pump to administer Withaferin A systemically to treat fundus lesions. There are also related basic studies internationally that believe that Withaferin A may also be able to treat corneal pathological angiogenesis, but all use systemic administration (such as subperitoneal injection). Mohan R, Bargagna-Mohan P, etc. Academic Press, 2016, Investigative Ophthalmology & Visual Science, 2012, PLoS One, 2015, Investigative Ophthalmology & Visual Science, 2005 Chemistry & Biology, 2007, 14 (6): 623-634. At present, all relevant studies are basic research, and withaferin A is simply dissolved and used systemically, and no attempt has ever been made to make it into related medicinal preparations. A large number of studies by our research group have confirmed that withaferin A is an anti-VEGF, angiogenesis-inhibiting compound. If it is used systemically, it will inhibit the formation of cardiovascular and cerebrovascular collateral circulation and easily induce cardiovascular and cerebrovascular accidents. Therefore, it is obviously more harmful than beneficial to make it into a medicinal preparation for systemic use. Therefore, our team turned to studying making it into an ophthalmic preparation for local use to avoid its cardiovascular and cerebrovascular side effects. When people wear contact lenses, contact lens care solution will directly act on the cornea, playing a role similar to eye drops, and it is more convenient to use. Therefore, our team made contact lens care solution with withaferin A and corresponding proportions of auxiliary materials to prevent the biggest hidden danger for people wearing contact lenses - corneal hypoxia damage and neovascularization. At present, there is no contact lens care solution that can inhibit corneal hypoxia damage and neovascularization, and there is no research report on withaferin A contact lens care solution. Summary of the invention
[0004] To achieve the above object, the technical solution adopted by the present invention is:
[0005] A contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization, comprising the following ingredients by weight to volume ratio: 0.01-0.5 mg / L withaferin A, 0.1-10 g / L disodium edetate, 1-25 g / L dissolution promoter, 2-40 g / L thickener, 0.04-0.2 g / L antibacterial agent, appropriate amounts of isotonicity regulator and pH regulator, and the balance being water for injection.
[0006] A further preferred embodiment is that the dissolution agent is one of Tween 80, propylene glycol, poloxamer, polyethylene glycol, and β-cyclodextrin, or a mixture of any of them.
[0007] A further preferred embodiment is that the thickener is one or a mixture of any of methyl cellulose, polyvinyl alcohol, polyethylene glycol, sodium hyaluronate, povidone, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, and carboxymethyl cellulose.
[0008] A further preferred embodiment is that the pH adjuster is one of boric acid, borate buffer, phosphate buffer, citrate buffer or a mixture of any of them, and the amount of the pH adjuster is based on adjusting the pH value of the care solution to 6.0-8.5.
[0009] A further preferred embodiment is that the osmotic pressure regulator is one of sodium chloride, potassium chloride, boric acid, glucose, and glycerol, or a mixture of any of them; and the amount of the osmotic pressure regulator is used to adjust the osmotic pressure molar concentration ratio to 0.9 to 1.1.
[0010] The method for preparing the contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization comprises the following steps:
[0011] The first step is to weigh the withaferin A and the solubilizing agent in the above weight-to-volume ratio, mix them and stir them evenly for later use;
[0012] Step 2: Weigh the above-mentioned weight-to-volume ratio of disodium edetate, thickener, pH adjuster, isotonic adjuster, and antibacterial agent, heat and stir in a 60° C. water bath until clear and translucent, and cool to room temperature;
[0013] The third step is to add the mixed solution of the first step to the solution of the second step, and make up the volume with water for injection to prepare a contact lens care solution;
[0014] The fourth step is to filter and sterilize the prepared care solution through a 0.22 μm microporous filter membrane and aseptically package it.
[0015] The care solution of the present invention has the following advantages:
[0016] (1) The contact lens care solution with added withaferin A reported in the present invention makes withaferin A have better solubility, fully exerts the anti-inflammatory, anti-oxidative stress and anti-VEGF effects of withaferin A itself, and compared with ordinary contact lens care, it not only has the moisturizing and cleaning effects of ordinary care solutions, but also directly acts on the cornea when wearing contact lenses, improves corneal tissue hypoxia and corneal neovascularization caused by wearing contact lenses, plays a preventive health care function, has clear effects, is easy to use, and has certain conversion value.
[0017] (2) The withaferin A contact lens care solution reported in the present invention is a transparent and clear liquid with good biocompatibility, moderate viscosity, and no irritation to the eyes.
[0018] (3) The withaferin A in the contact lens care solution added withaferin A disclosed in the present invention has good solubility and permeability, and a traditional antibacterial agent (such as polyhexamethylene biguanide) can be added at the same time to enhance the antibacterial function of the care solution. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 It is Withaferin A contact lens solution that improves corneal angiogenesis in mice caused by alkali burns, while traditional contact lens solution has no obvious effect.
[0020] Figure 2 Withaferin A contact lens care solution improved the corneal angiogenesis in mice induced by suture method, while traditional contact lens care solutions had no obvious effect. DETAILED DESCRIPTION
[0021] The following examples and experimental examples are merely provided to further illustrate the present invention and should not be construed as limiting the present invention.
[0022] Example 1 DETAILED DESCRIPTION
[0024] The following examples and experimental examples are merely provided to further illustrate the present invention and should not be construed as limiting the present invention.
[0025] Example 1
[0026] The present embodiment describes a contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization. The withaferin A contact lens care solution contains the following ingredients by weight to volume ratio: 0.01 mg / L withaferin A, 0.5 g / L edetate disodium, 1 g / L Tween 80, 5.6 g / L povidone K30, 0.1 g / L benzalkonium chloride, 6.2 g / L sodium chloride, 4 g / L sodium dihydrogen phosphate, 7.1 g / L sodium hydrogen phosphate, and the balance is water for injection.
[0027] The dosage of the sodium dihydrogen phosphate and disodium hydrogen phosphate is based on adjusting the pH value of the contact lens care solution to 6.8.
[0028] The amount of sodium chloride used is to adjust the osmotic pressure molar concentration ratio to 0.9.
[0029] The method for preparing a contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization comprises the following steps:
[0030] The first step is to weigh withaferin A and Tween 80 in a corresponding weight-to-volume ratio, mix them and stir them evenly for later use;
[0031] Step 2: Weigh corresponding weight-volume ratios of edetate disodium, povidone K30, benzalkonium chloride, sodium chloride, sodium dihydrogen phosphate, and sodium hydrogen phosphate, heat and stir in a 60° C. water bath until clear and translucent, and cool to room temperature;
[0032] The third step is to add the mixed solution of the first step to the solution of the second step and make up to volume with water for injection;
[0033] The fourth step is to filter and sterilize the prepared care solution through a 0.22 μm microporous filter membrane and aseptically package the solution.
[0034] The contact lens care solution is used for treating corneal hypoxia damage and corneal neovascularization caused by wearing contact lenses.
[0035] Example 2
[0036] The present embodiment describes a contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization. The withaferin A contact lens care solution contains the following ingredients by weight to volume ratio: 0.1 mg / L withaferin A, 1 g / L disodium edetate, 5 g / L Tween 80, 5.6 g / L povidone K30, 0.1 g / L benzalkonium chloride, 6.2 g / L sodium chloride, 4 g / L sodium dihydrogen phosphate, 7.1 g / L disodium hydrogen phosphate, and the balance is water for injection.
[0037] The dosage of the sodium dihydrogen phosphate and disodium hydrogen phosphate is based on adjusting the pH value of the contact lens care solution to 6.8.
[0038] The amount of sodium chloride used is to adjust the osmotic pressure molar concentration ratio to 0.9.
[0039] The method for preparing a contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization comprises the following steps: first, weighing withaferin A and Tween 80 in a corresponding weight-to-volume ratio, mixing them and stirring them evenly for later use;
[0040] Step 2: Weigh corresponding weight-volume ratios of edetate disodium, povidone K30, benzalkonium chloride, sodium chloride, sodium dihydrogen phosphate, and sodium hydrogen phosphate, heat and stir in a 60° C. water bath until clear and translucent, and cool to room temperature;
[0041] The third step is to add the mixed solution of the first step to the solution of the second step and make up to volume with water for injection;
[0042] The fourth step is to filter and sterilize the prepared care solution through a 0.22 μm microporous filter membrane and aseptically package the solution.
[0043] The contact lens care solution is used for treating corneal hypoxia damage and corneal neovascularization caused by wearing contact lenses.
[0044] Example 3
[0045] The present embodiment describes a contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization. The withaferin A contact lens care solution contains the following ingredients by weight to volume ratio: 0.5 mg / L withaferin A, 5 g / L edetate disodium, 10 g / L Tween 80, 5.6 g / L povidone K30, 0.1 g / L benzalkonium chloride, 6.2 g / L sodium chloride, 4 g / L sodium dihydrogen phosphate, 7.1 g / L sodium hydrogen phosphate, and the balance is water for injection.
[0046] The dosage of the sodium dihydrogen phosphate and disodium hydrogen phosphate is based on adjusting the pH value of the contact lens care solution to 6.8.
[0047] The amount of sodium chloride used is to adjust the osmotic pressure molar concentration ratio to 0.9.
[0048] The method for preparing a contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization comprises the following steps: first, weighing withaferin A and Tween 80 in a corresponding weight-to-volume ratio, mixing them and stirring them evenly for later use;
[0049] Step 2: Weigh corresponding weight-volume ratios of edetate disodium, povidone K30, benzalkonium chloride, sodium chloride, sodium dihydrogen phosphate, and sodium hydrogen phosphate, heat and stir in a 60° C. water bath until clear and translucent, and cool to room temperature;
[0050] The third step is to add the mixed solution of the first step to the solution of the second step and make up to volume with water for injection;
[0051] The fourth step is to filter and sterilize the prepared care solution through a 0.22 μm microporous filter membrane and aseptically package the solution.
[0052] The contact lens care solution is used for treating corneal hypoxia damage and corneal neovascularization caused by wearing contact lenses.
[0053] The dissolution promoter may also be one of propylene glycol, poloxamer, polyethylene glycol, and β-cyclodextrin, or a mixture of any of Tween 80, propylene glycol, poloxamer, polyethylene glycol, and β-cyclodextrin.
[0054] The thickener can also be one of polyvinyl alcohol, polyethylene glycol, sodium hyaluronate, povidone, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, carboxymethyl cellulose, or a mixture of any of methylcellulose, polyvinyl alcohol, polyethylene glycol, sodium hyaluronate, povidone, hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose, and carboxymethyl cellulose.
[0055] The pH regulator can also be one of borate buffer, phosphate buffer, citrate buffer or a mixture of boric acid, borate buffer, phosphate buffer and citrate buffer. The amount of the pH regulator is based on adjusting the pH value of the care solution to 6.0-8.5.
[0056] The osmotic pressure regulator can also be one of potassium chloride, boric acid, glucose, and glycerol, or a mixture of any of sodium chloride, potassium chloride, boric acid, glucose, and glycerol; and the amount of the osmotic pressure regulator is used to adjust the osmotic pressure molar concentration ratio to 0.9 to 1.1.
[0057] The antibacterial agent can also be one of benzalkonium chloride, benzalkonium bromide and polyquaternium-1, or a mixture of any of ethylparaben, benzalkonium chloride, benzalkonium bromide and polyquaternium-1.
[0058] In order to further demonstrate the effects and effects of the present invention, the in vivo experimental results of two animal models are provided as follows:
[0059] In order to further demonstrate the effects and effects of the present invention, the in vivo experimental results of two animal models are provided as follows:
[0060] like Figure 1 As shown, withaferin A contact lens solution improves corneal angiogenesis in mice induced by alkali burns, while traditional contact lens solution has no significant effect
[0061] This experiment selected the classic mouse corneal alkali burn model to induce corneal angiogenesis. Healthy wild-type female C57 mice, aged 6-8 weeks. All mice had shiny hair, no hair loss, no abnormalities in eye examination, clear refractive media, and normal fundus. They were randomly divided into: 1. control group; 2. alkali burn group; 3. alkali burn + traditional contact lens care solution group; 4. alkali burn + WFA (withaferin A) contact lens care solution group, 20 mice in each group. Among them, groups 3 and 4 were given care solution once a day, and the eye drop intervention simulated the daily use frequency of contact lens care solution. After 14 days of intervention, corneal angiogenesis was scored under a microscope according to the following method: 0 = no neovascularization, no new blood vessels at the limbus; 1 = mild neovascularization, new blood vessels from the limbus; 2 = moderate neovascularization, blood vessels originating from the limbus and growing toward the center of the cornea; 3 = severe neovascularization, blood vessels starting from the limbus and reaching and / or passing through the center of the cornea. Figure 1 The results showed that withaferin A contact lens solution significantly improved corneal angiogenesis in mice, while the traditional contact lens solution group did not significantly improve corneal angiogenesis in mice. Figure 1 NS = no difference, **p < 0.01.
[0062] like Figure 2As shown, withaferin A contact lens solution improved corneal angiogenesis in mice induced by suture method, while traditional contact lens solution had no significant effect.
[0063] This experiment chose the classic suture method to induce corneal angiogenesis. Healthy wild-type female ICR mice, aged 6-8 weeks. All mice had shiny hair without hair loss, no abnormalities were found in eye examination, clear refractive media, and normal fundus. They were randomly divided into: 1. Control group; 2. Suture group; 3. Suture + traditional contact lens care solution group; 4. Suture + WFA contact lens care solution group, 20 mice in each group. Among them, groups 3 and 4 were given care solution once a day to simulate the daily use frequency of contact lens care solution. After 14 days of intervention, if Figure 2 Under a microscope, the angiogenesis of each group was compared by counting the angiogenesis area. The results showed that the Withaferin A care solution significantly improved the angiogenesis of the mouse cornea, while the Withaferin A solution did not significantly improve the angiogenesis of the mouse cornea. Figure 2 NS = no difference, ***p<0.001.
[0064] The in vivo experimental results of the above two animal models show that the use of traditional contact lens care solutions has no improvement effect on corneal angiogenesis. The Withaferin A contact lens care solution with added Withaferin A and corresponding solvents described in this patent acts directly on the cornea when wearing contact lenses. It not only has the moisturizing and cleaning effects of conventional care solutions, but also prevents the biggest hidden danger of people wearing contact lenses - corneal hypoxia damage and neovascularization. It has clear effects, is easy to use, and has clear application value and market value.
Claims
1. A contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization, characterized in that: Calculated by weight to volume ratio, it contains the following ingredients: withaferin A 0.01-0.5 mg / L, edetate disodium 0.1%-10% g / L, dissolution promoter 1-25 g / L, thickener 2-40 g / L, antibacterial agent 0.04-0.2 g / L, appropriate amounts of isotonic regulator and pH regulator, and the balance is water for injection.
2. The contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization according to claim 1, characterized in that: The dissolution promoter is one of Tween 80, propylene glycol, poloxamer, polyethylene glycol, and beta-cyclodextrin, or a mixture of any of the above.
3. The contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization according to claim 1, characterized in that: The thickener is one or a mixture of any of methyl cellulose, polyvinyl alcohol, polyethylene glycol, sodium hyaluronate, povidone, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, and carboxymethyl cellulose.
4. The contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization according to claim 1, characterized in that: The pH regulator is one of boric acid, borate buffer, phosphate buffer, citrate buffer or a mixture of any of the above. The amount of the pH regulator is based on adjusting the pH value of the care solution to 6.0-8.
5.
5. The contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization according to claim 1, characterized in that: The osmotic pressure regulator is one of sodium chloride, potassium chloride, boric acid, glucose, and glycerol, or a mixture of any of them; and the dosage of the osmotic pressure regulator is to adjust the osmotic pressure molar concentration ratio to 0.9-1.
1.
6. A method for preparing a contact lens care solution for inhibiting corneal hypoxia damage and corneal neovascularization according to any one of claims 1 to 5, characterized in that: The preparation method comprises the following steps: The first step is to weigh the withaferin A and the solubilizing agent in the above weight-to-volume ratio, mix them and stir them evenly for later use; Step 2: Weigh the above-mentioned weight-to-volume ratio of disodium edetate, thickener, pH adjuster, isotonic adjuster, and antibacterial agent, heat and stir in a 60° C. water bath until clear and translucent, and cool to room temperature; The third step is to add the mixed solution of the first step to the solution of the second step, and make up the volume with water for injection to prepare a contact lens care solution; The fourth step is to filter and sterilize the prepared care solution through a 0.22 μm microporous filter membrane and aseptically package it.
Citation Information
Patent Citations
Contact lens packaging solution and preparing method thereof
CN106010805A
Application of Withaferin A in preparing drug for treating fundus ischemic disease
CN110151769A
Contact lens care solution and preparation method
CN111518627A
Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases
CN112996486A
Application of drunkanin A compound
CN118161510A
